FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising an anti-TROP2 antibody-drug conjugate, a method of producing an anti-TROP2 antibody-drug conjugate, a pharmaceutical composition for the treatment and/or prevention of TROP2-positive gastric cancer, use of the conjugate or pharmaceutical composition in the manufacture of a TROP2 protein inhibitor, use of the conjugate or pharmaceutical composition for treating and/or preventing TROP2-positive gastric cancer.
EFFECT: invention extends the range of TROP2 binding agents.
12 cl, 1 dwg, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY-DRUG CONJUGATE, INTERMEDIATE FOR ITS PRODUCTION, METHOD OF ITS PRODUCTION AND ITS USE | 2020 |
|
RU2800137C1 |
| ANTIBODY AND DRUG CONJUGATES FOR DESTRUCTION OF HEMATOPOIETIC STEM CELLS | 2017 |
|
RU2781444C2 |
| CALICHEAMICIN DERIVATIVES AND THEIR ANTIBODY-DRUG CONJUGATES | 2018 |
|
RU2732568C1 |
| ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 2014 |
|
RU2743077C2 |
| MAITANZINOID DERIVATIVES WITH SELF-SPLITTING PEPTIDE LINKERS AND THEIR CONJUGATES | 2018 |
|
RU2765098C2 |
| CONJUGATE ANTIBODY-DERIVATIVE OF PYRROLOBENZODIAZEPINE | 2018 |
|
RU2820928C2 |
| ANTIBODY-DRUG CONJUGATES CONTAINING HERBOXYDIENE-BASED SPLICING MODULATOR, AND METHODS OF USE THEREOF | 2019 |
|
RU2820607C2 |
| ANTIBODY TO B7H3-EXATECAN ANALOGUE CONJUGATE AND ITS USE IN MEDICINE | 2019 |
|
RU2785664C2 |
| “CYSTEINE-MODIFIED ANTIBODY-DRUG” CONJUGATE AND ITS PRODUCTION METHOD | 2017 |
|
RU2762594C2 |
| ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2776489C2 |
